Erratum to: Safety and Tolerability of Levomilnacipran ER in Major Depressive Disorder: Results from an Open-Label, 48-Week Extension Study

Ítems similars

• Safety and Tolerability of Levomilnacipran ER in Major Depressive Disorder: Results from an Open-Label, 48-Week Extension Study
  per: Mago, Rajnish, et al.
  Publicat: (2013)
• A Randomized, Double-blind, Placebo-controlled Trial of the Efficacy and Safety of Levomilnacipran ER 40-120mg/day for Prevention of Relapse in Patients with Major Depressive Disorder
  per: Shiovitz, Thomas, et al.
  Publicat: (2014)
• Effects of levomilnacipran ER on fatigue symptoms associated with major depressive disorder
  per: Freeman, Marlene P., et al.
  Publicat: (2016)
• A randomized, double-blind, placebo-controlled study of flexible doses of levomilnacipran ER (40–120 mg/day) in patients with major depressive disorder
  per: Gommoll, Carl P., et al.
  Publicat: (2014)
• Efficacy of levomilnacipran extended-release in improving functional impairment associated with major depressive disorder: pooled analyses of five double-blind, placebo-controlled trials
  per: Sambunaris, Angelo, et al.
  Publicat: (2014)